Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 30 of 99
Full-Text Articles in Medicine and Health Sciences
Oncolog, Volume 63, Number 08, August 2018, Angie N. Meus, Joe Munch, Bryan Tutt
Oncolog, Volume 63, Number 08, August 2018, Angie N. Meus, Joe Munch, Bryan Tutt
OncoLog MD Anderson's Report to Physicians (All issues)
- High-Dose Radiation Therapy for Pancreatic Cancer: trial tests whether radiomodulating agent GC4419 can enable higher doses of stereotactic body radiation therapy
- Image-Guided Cordotomy for Cancer Pain: Computed tomography-guided cordotomy relieves cancer-related refractory pain
- Esophageal, Pharyngoesophageal Reconstruction: Advanced surgical techniques restore digestive continuity
- Therapy Preserves Swallowing Function: New trial tests different swallowing therapy regimens for head and neck cancer patients undergoing radiation therapy
- OncoLog Says Farewell
Oncolog, Volume 63, Number 07, July 2018, Sarah Bronson, Bryan Tutt
Oncolog, Volume 63, Number 07, July 2018, Sarah Bronson, Bryan Tutt
OncoLog MD Anderson's Report to Physicians (All issues)
- FGFR Inhibition for Bladder Cancer: Erdafitinib has favorable response rate in advanced bladder cancers, including those that do not respond to immunotherapy
- INBRIEF: Targeted Therapies Matched to Tumor-Specific Mutations Prolong Survival
- Managing High-Risk Breast Lesions: Strong provider recommendation for preventive therapy increases its use in women with lobular carcinoma in situ, atypical hyperplasia
- Aerosolized Gemcitabine for Pulmonary Metastases: Clinical trials tests novel chemotherapy delivery system for patients with lung metastases from osteosarcoma or other solid tumors
- HOUSE CALL: What the national Cancer Institute Does- Resources for cancer patients, caregivers, physicians, researchers
Oncolog, Volume 63, Number 05-06, May - June 2018, Joe Munch, Sunita Patterson, Bryan Tutt
Oncolog, Volume 63, Number 05-06, May - June 2018, Joe Munch, Sunita Patterson, Bryan Tutt
OncoLog MD Anderson's Report to Physicians (All issues)
- Breast Cancer Treatment without Surgery: New approach may let certain breast cancer patients who respond to systemic therapy forgo surgery
- INBRIEF: Targeted Drug BLU-667 Shows Promise against Solid Tumors with RET Alterations
- Diet May Improve Gut Microbiome in Colorectal Cancer Survivors: Trial tests whether adding beans to diet affects markers of cancer risk, metabolic health
- TRK Inhibition Shows Activity in Solid Tumors: Early results of clinical trials for adult, pediatric patients with NTRK gene fusions show promise
- HOUSE CALL: Preparing for Natural Disasters-People with cancer or other chronic illnesses should take extra precautions
Oncolog, Volume 63. Number 03, March 2018, Bryan Tutt
Oncolog, Volume 63. Number 03, March 2018, Bryan Tutt
OncoLog MD Anderson's Report to Physicians (All issues)
- Local Consolidative Therapy Plus Immunotherapy or Targeted Agents for NSCLC: Clinical trials explore surgery/radiation plus immune checkpoint or tyrosine kinase inhibitors for metastatic non-small cell lung cancer
- INBRIEF: CAR T Cells Elicit Durable Responses in Large B Cell Lymphoma
- Managing Opioid Use in Cancer Patients: Vigilance and interventions ensure patient safety
- Hepatitis C Virus Linked to Head and Neck Cancers: Association of HCV with extrahepatic cancers has implications for HCV testing, treatment
- HOUSE CALL: Understanding cancer Risk and Risk factors-Your risk factors might affect your need for cancer screening
Oncolog, Volume 63, Number 02, February 2018, Sarah Bronson, Bryan Tutt
Oncolog, Volume 63, Number 02, February 2018, Sarah Bronson, Bryan Tutt
OncoLog MD Anderson's Report to Physicians (All issues)
- Radiation Therapy for Liver Cancer: Clinical trials expand treatment options for patients with primary liver cancer
- Proton Therapy for Breast Cancer May Avoid Heart Damage: Trial compares cardiotoxicity of proton-and photon-based radiation therapy to the breast/chest wall and lymph nodes
- New targeted Therapies for Leukemia: New treatments target CD123, BCL2 proteins in acute myelogenous leukemia, blastic plasmacytoid dendritic cell neoplasm
- HOUSE CALL: Supportive Care for Cancer Patients- Supportive care treats the whole patient, not just the cancer
Oncolog, Volume 63, Number 01, January 2018, Bryan Tutt
Oncolog, Volume 63, Number 01, January 2018, Bryan Tutt
OncoLog MD Anderson's Report to Physicians (All issues)
- Immunotherapy for Genitourinary Cancers: Clinical trials explore immune checkpoint inhibitors for bladder, kidney, prostate cancers
- Active Surveillance for Ductal Carcinoma in Situ: COMET trial compares frequent mammography to standard treatment with surgery
- Radiation Plus Chemotherapy for Nasal NK T Cell Lymphoma: Clinical trial may standardize treatment for rare cancer
- HOUSE CALL: Mammography Is Essential for Breast cancer Screening- FDA warns against clinics that advertise screening without mammography
- USEFULRESOURCES: Videoconferences Allow Collaboration in Cancer Prevention, Treatment, Survivorship
Oncolog, Volume 62, Number 09, September 2017, Joe Munch, Bryan Tutt
Oncolog, Volume 62, Number 09, September 2017, Joe Munch, Bryan Tutt
OncoLog MD Anderson's Report to Physicians (All issues)
- Laser Interstitial Thermal Therapy for Spinal Metastases: Laser technique may be alternative to open surgery prior to stereotactic radiation therapy for metastases adjacent to the spinal cord.
- Immunotherapy Plus Targeted Therapy for Anaplastic Thyroid Cancer: Trial combines atezolizumab with targeted or cytotoxic agents for patients with anaplastic or poorly differentiated thyroid cancer.
- A New era in Follicular Lymphoma: Newly approved drugs, clinical trials represent shift from cytotoxic to targeted and immunotherapeutic agents.
- HOUSE CALL: Understanding Clinical Trials- Trials provide access to new cancer treatments
- INBRIEF: Repeat Surgery for Close Margins May Be Unnecessary for DCIS Patients Receiving Radiation Therapy
Oncolog, Volume 62, Number 08, August 2017, Bryan Tutt, Sarah Bronson
Oncolog, Volume 62, Number 08, August 2017, Bryan Tutt, Sarah Bronson
OncoLog MD Anderson's Report to Physicians (All issues)
- Immunotherapy for Smoldering Myeloma: Clinical trials test PD-1, DC38 inhibitors to delay progression from premalignant disease to multiple myeloma.
- Malignant Pheochromocytoma and Sympathetic Paraganglioma Research: Studies may expand treatment options for patients with rare neuroendocrine tumors.
- Hypofractionated Partial-Breast Irradiation: Clinical trial tests 10-day external-beam radiation therapy regimen after lumpectomy for patients with early-stage breast cancer.
- HOUSE CALL: Support for Cancer Patients: Patients, caregivers find many types of support from various organizations
Oncolog, Volume 62, Number 07, July 2017, Joe Munch, Bryan Tutt
Oncolog, Volume 62, Number 07, July 2017, Joe Munch, Bryan Tutt
OncoLog MD Anderson's Report to Physicians (All issues)
- RAS Mutations and Colorectal Cancer Liver Metastases: Gene mutations may have implications for local therapy for liver metastases from colorectal cancer.
- Active Surveillance for Prostate Cancer: Clinical trial may clarify which patients with prostate cancer will benefit from active surveillance rather than immediate treatment.
- Gut Microbiome May Affect Immunotherapy Response in Melanoma: Metastatic melanoma patients who experience responses to checkpoint inhibitors have a distinct gut bacterial genetic signature.
- HOUSE CALL: Cancer-Related fatigue-Tips for fighting fatigue
Oncolog, Volume 62, Number 05-06, May - June 2017, Joe Munch, Bryan Tutt, Kathryn Hale
Oncolog, Volume 62, Number 05-06, May - June 2017, Joe Munch, Bryan Tutt, Kathryn Hale
OncoLog MD Anderson's Report to Physicians (All issues)
- Chimeric Antigen Receptor-Directed Natural Killer Cells for B Cell Malignancies: New take on an experimental therapy holds promise for patients with acute lymphoblastic leukemia, chronic lymphocytic leukemia, other lymphoid cancers.
- Preoperative Exercise Program for Pancreatic Cancer Patients: Prehabilitation regimen to improve functional status during chemotherapy evaluated in clinical trials.
- Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer: Clinical Trial will evaluate immune checkpoint inhibitors in patients with operable early-stage disease.
- HOUSE CALL: Genetic Screening for Hereditary Cancer Syndromes: Genetic counseling, testing help people assess, manage cancer risk
Oncolog, Volume 62, Number 04, April 2017, Bryan Tutt, Sarah Bronson
Oncolog, Volume 62, Number 04, April 2017, Bryan Tutt, Sarah Bronson
OncoLog MD Anderson's Report to Physicians (All issues)
- Advances in Surgical Management of Lymphedema: New options reduce edema in limbs, improve quality of life for cancer patients with lymphedema.
- Noncytotoxic First-Line Therapy for Mantle Cell Lymphoma: First-line therapy with targeted and immunotherapy agents produces high response rates in mantle cell lymphoma.
- Reports from the Survivorship Research Symposium: Research on BK virus, heart failure, and aspiration in cancer survivors.
- HOUSE CALL: Types of Immunotherapy for Cancer: Understanding different approaches to immunotherapy
Oncolog, Volume 62, Number 03, March 2017, Bryan Tutt, Joe Munch, Brandon C. Strubberg
Oncolog, Volume 62, Number 03, March 2017, Bryan Tutt, Joe Munch, Brandon C. Strubberg
OncoLog MD Anderson's Report to Physicians (All issues)
- Immunotherapy for Glioblastoma: Clinical trials test innovative immunotherapy approaches against brain tumors.
- Virus-Specific T Cells Treat Posttransplant Infections: Banked T cells offer "off-the-shelf" therapy for patients with BK virus, JC virus, Cytomegalovirus infections after stem cell transplant.
- Intensity-Modulated Proton Therapy for Oropharyngeal Cancer: Clinical trial compares outcomes of intensity-modulated proton therapy, standard radiation therapy.
- HOUSE CALL: Lung Cancer Screening-Low-dose computed tomography can detect lung cancer early
Oncolog, Volume 62, Number 01, January 2017, Bryan Tutt, Joe Munch, Z Ahmed
Oncolog, Volume 62, Number 01, January 2017, Bryan Tutt, Joe Munch, Z Ahmed
OncoLog MD Anderson's Report to Physicians (All issues)
- Neoadjuvant Immunotherapy for Melanoma: Trial investigates immune checkpoint blockade in patients with respectable stage III or oligometastatic stage IV disease.
- Radiation May Enhance Immunotherapy for Solid Tumors: Clinical Trials combine immune checkpoint inhibitors with radiation therapy against lung cancers, other solid tumors.
- INBRIEF: Nivolumab Plus Azacitidine Shows Promise in Relapsed Acute Myelogenous Leukemia/ Acute Myelogenous Leukemia, Myelodysplastic Syndrome Study Questions Standard Exclusion Criteria for Conventional Trials
- HOUSE CALL: Social Media Groups for Cancer Patients-Twitter chats, online groups for patients, caregivers
- USEFUL RESOURCES: Resources to Aid Referring Physicians
Oncolog, Volume 61, Number 11-12, November - December 2016, Brandon C. Strubberg, Sarah Bronson, Stephanie Deming, E Nielsen
Oncolog, Volume 61, Number 11-12, November - December 2016, Brandon C. Strubberg, Sarah Bronson, Stephanie Deming, E Nielsen
OncoLog MD Anderson's Report to Physicians (All issues)
- Innovative Trial Investigates Molecular Drivers of Triple-Negative Breast Cancer: A new clinical trial focusing on molecular biomarkers of triple-negative breast cancer (TNBC) is attempting to advance targeted therapy against the deadly disease.
- Smac Mimetics Show Activity against Myelofibrosis: Not all cases of myelofibrosis respond well to ruxolitinib, the only drug approved for this disease. However, early studies indicate that a new class of drugs, Smac mimetics, can achieve a response in some patients with myelofibrosis.
- Urothelial Cancer Subtypes Predict Treatment Response: Subtypes of urothelial cancer identified through gene expression profiling predict which patients are most likely to respond to neoadjuvant …
Oncolog, Volume 61, Number 10, October 2016, Laura L. Russell, Joe Munch, Bryan Tutt, Z Ahmed
Oncolog, Volume 61, Number 10, October 2016, Laura L. Russell, Joe Munch, Bryan Tutt, Z Ahmed
OncoLog MD Anderson's Report to Physicians (All issues)
- Preventing Postoperative Urinary Tract Infections in Cancer Patients: Urinary tract infections (UTIs) increase morbidity, mortality and health care costs and prolong hospitalizations for patients who require urinary catheters-especially those who undergo long, complex surgeries or procedures to treat urological or gynecological cancers. To reduce the incidence of UTIs, clinicians at The University of Texas MD Anderson Cancer Center developed a quality improvement program for surgical patients at the institution.
- Study Offers a Starting Point for Testing Immunotherapy in Rectal Cancer Patients with Deficient DNA Mismatch Repair: A recent study's findings provide a starting point for assessing the efficacy of immunotherapy …
Oncolog, Volume 61, Number 08, August 2016, Joe Munch, Bryan Tutt, E Nielsen
Oncolog, Volume 61, Number 08, August 2016, Joe Munch, Bryan Tutt, E Nielsen
OncoLog MD Anderson's Report to Physicians (All issues)
- Finding a Way Forward in Parathyroid Carcinoma: Among the rarest of the rare malignancies, parathyroid carcinoma poses myriad diagnostic and treatment challenges. Owing to its extreme rarity, very little is known about the mechanisms driving parathyroid carcinoma, let alone how to target them; and survival rates have not budged in decades. However researchers at The University of Texas MD Anderson Cancer Center are working to change this.
- Studies Explore Screening for HPV-related Anal and Oropharyngeal Cancers: No consensus screening guidelines exist for human papillomavirus (HPV)-related cancers other than cervical cancer. As a step toward establishing such guidelines, studies under way …
Oncolog, Volume 61, Number 07, July 2016, Bryan Tutt, Sarah Bronson, Laura Russell
Oncolog, Volume 61, Number 07, July 2016, Bryan Tutt, Sarah Bronson, Laura Russell
OncoLog MD Anderson's Report to Physicians (All issues)
- Improving Rates of Vaccination after Hematopoietic Stem Cell Transplant: Patients who have undergone a hematopoietic stem cell transplant (HSCT) for a hematological cancer usually lose the immunity they had acquired through vaccination. Although guidelines exist for vaccinating immunocompromised transplant recipients, many patients go unvaccinated or do not complete the series of vaccinations. An ongoing initiative at The University of Texas MD Anderson Cancer Center is using a multipronged approach to improve rates of vaccination after HSCT.
- Bone Loss Prevention in Patients with Cancer: Patients undergoing cancer treatment are at an increased risk of fractures because many cancer therapies tend to …
Oncolog, Volume 61, Number 06, June 2016, Jill Deisigne, Joe Munch, Kathryn Hale, B Strubberg
Oncolog, Volume 61, Number 06, June 2016, Jill Deisigne, Joe Munch, Kathryn Hale, B Strubberg
OncoLog MD Anderson's Report to Physicians (All issues)
- Proton Therapy Trials May Provide More Options for Patients with Non-Small Cell Lung Cancer: Proton therapy offers the potential to deliver a higher radiation dose to lung tumors and a lower dose to healthy tissues than does standard radiation therapy. However, the effectiveness of proton therapy has not yet been documented in clinical trials for patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer. Two ongoing trials of proton therapy aim to demonstrate its effectiveness and may change the standard of care for NSCLC.
- Innovative "Basket" Trial Shows Promise of BRAF Inhibition in Various Cancers: …
Oncolog, Volume 61, Number 05, May 2016, Bryan Tutt, Katelyn Werner
Oncolog, Volume 61, Number 05, May 2016, Bryan Tutt, Katelyn Werner
OncoLog MD Anderson's Report to Physicians (All issues)
- Intratumoral Therapies Offer Novel Cancer Treatment Approach: Injecting cancer treatments such as vaccines and genetically modified bacteria and viruses directly into tumors may shrink or destroy the tumors and stimulate an immune response that attacks tumor cells. These treatments have shown promise in clinical trials, and newer trials are exploring whether such treatments can augment the effectiveness of immunotherapy in patients with metastatic or inoperable disease.
- High-Risk Acute Lymphoblastic Leukemia Subtype Targeted in Upcoming Clinical Trial: Early T cell precursor acute lymphoblastic leukemia (ETP-ALL), an uncommon subtype of T cell acute lymphoblastic leukemia (T-ALL), carries a poor prognosis and low …
Oncolog, Volume 61, Number 04, April 2016, Joe Munch, Bryan Tutt, K Werner
Oncolog, Volume 61, Number 04, April 2016, Joe Munch, Bryan Tutt, K Werner
OncoLog MD Anderson's Report to Physicians (All issues)
- Aggressive Multimodality Salvage Therapy for Locally Recurrent Rectal Cancer Offers Hope to Patients: For patients with locally recurrent rectal cancer, multimodality salvage therapy presents the only chance for a cure. Such therapy is offered at just a handful of specialized referral institutions, including The University of Texas MD Anderson Cancer Center.
- Rapid Assessment, Clinical Trials Could Improve Outcomes for Anaplastic Thyroid Cancer Patients: Anaplastic thyroid cancer is extremely aggressive-only 20% of patients survive 1 year after their diagnosis-so patients require immediate assessment and treatment. A program at The University of Texas MD Anderson Cancer Center expedites the care of patients …
Oncolog, Volume 61, Number 03, March 2016, Bryan Tutt, Sarah Bronson, Jill Deisigne, K Werner
Oncolog, Volume 61, Number 03, March 2016, Bryan Tutt, Sarah Bronson, Jill Deisigne, K Werner
OncoLog MD Anderson's Report to Physicians (All issues)
- Innovations Decrease Toxic Effects of Radiation Therapy for Mediastinal Tumors from Hematological Malignancies: Anterior mediastinal masses caused by lymphoma or leukemia can be difficult to treat because sensitive tissues in the area are vulnerable to damage from radiation therapy. To treat these tumors while sparing healthy tissue, radiation oncologists at The University of Texas MD Anderson Cancer Center use a combination of advanced technologies and new techniques.
- Transoral Robotic Surgery Enables Less Toxic Treatment of Early Throat Cancers: For decades, many patients with hard-to-reach throat cancers received high-dose radiation and chemotherapy, with their often severe toxic effects, because conventional surgery …
Oncolog, Volume 61, Number 01, January 2016, Sarah Bronson, Bryan Tutt, Bryan Tutt
Oncolog, Volume 61, Number 01, January 2016, Sarah Bronson, Bryan Tutt, Bryan Tutt
OncoLog MD Anderson's Report to Physicians (All issues)
- Proactive Management of Li-Fraumeni Syndrome Benefits Patients: Li-Fraumeni syndromes a hereditary disorder that confers an extremely high likelihood of developing cancer on affected individuals.
- Clinical Trial Tests High-Dose Radiation Therapy for Limited Stage Small Cell Lung Cancer: Small cell lung cancer carries a poor prognosis, even for patients without metastatic disease. But a phase III trial of high-dose daily or accelerated twice-daily thoracic radiation therapy for limited stage small cell kung cancer may lead to longer survival.
- Reducing Complications and Hospital Readmissions after Liver Surgery: Hepatectomy carries a risk of complications that can lead to hospital readmission and even death. …
Oncolog, Volume 60, Number 09, September 2015, Sarah Bronson, Bryan Tutt, K. Nair
Oncolog, Volume 60, Number 09, September 2015, Sarah Bronson, Bryan Tutt, K. Nair
OncoLog MD Anderson's Report to Physicians (All issues)
- Enhanced Surgical Recovery Programs Improve Perioperative Outcomes for Cancer Patients: For patients undergoing cancer surgery, potential complications and long recovery times can delay the delivery of additional life-saving therapy. To improve patients' perioperative outcomes and clear the way for timely administration of additional therapies, several surgical teams at The University of Texas MD Anderson Cancer Center gave begun using enhanced surgical recovery programs (ESRPs).
- New Treatments for Respiratory Viruses in Immunocompromised Patients: Viral respiratory infections are a major concern for immunocompromised patients, in whom such infections are difficult to treat and can lead to pneumonia and even death. Although few …
Oncolog, Volume 60, Number 08, August 2015, Stephanie Deming, Bryan Tutt, K. Nair
Oncolog, Volume 60, Number 08, August 2015, Stephanie Deming, Bryan Tutt, K. Nair
OncoLog MD Anderson's Report to Physicians (All issues)
- New Gene Therapy for Bladder Cancer Shows Promise: A gene therapy that stimulates interferon production within the body may prove to be effective against high-risk, early-stage bladder cancer when standard treatment fails.
- Vaccine Helps T Cells Target Sarcomas, Melanomas and other Tumors: A vaccine that delivers an antigen to dendritic cells, in turn activating killer T cells that can target specific cancers, is the subject of two ongoing clinical trials,
- INBRIEF: Glypican-1 Shows Promise as a Biomarker for Pancreatic Cancer/Stereotactic Ablative Radiation Therapy for Stage I Non-Small Cell Lung Cancer May Offer Survival Benefit
- HOUSE CALL: Prostate Cancer Screening-Who should …
Oncolog, Volume 57, Number 05, May 2012, Bryan Tutt, Sunni Hosemann
Oncolog, Volume 57, Number 05, May 2012, Bryan Tutt, Sunni Hosemann
OncoLog MD Anderson's Report to Physicians (All issues)
- Advances in Gene Mapping Technology May Accelerate Cancer Drug Development: As new technology makes DNA sequencing faster and less expensive, researchers aim to exploit these abilities to develop novel targeted cancer therapies
- Compass: Advanced Renal Cell Carcinoma: Surgery and/or systemic therapy can help manage disease
- HOUSE CALL: Do Nutritional Supplements Help Prevent Cancer ?: For many people, the risks may outweigh the benefits
- INBRIEF: Drug Provides Symptom Reduction and Survival Advantages for Myelofibrosis Patients
Oncolog, Volume 57, Number 04, April 2012, Joe Munch, Bryan Tutt
Oncolog, Volume 57, Number 04, April 2012, Joe Munch, Bryan Tutt
OncoLog MD Anderson's Report to Physicians (All issues)
- Biology, More Than Chemotherapy Timing, Drives Locoregional Recurrence in Patients Who Undergo Breast-Conserving Therapy: The management of breast cancer, like that of many cancers, often requires a little bit of everything: surgery, radiation therapy, and systemic therapy with chemotherapeutic drugs or other agents
- New Treatments for Acute Myelogenous Leukemia May Improve Patient Outcomes: Acute myelogenous leukemia (AML) is an aggressive and deadly malignancy, nut new treatments are being developed that may prolong remissions
- HOUSE CALL: Controlling Nausea and Vomiting from Chemotherapy: Several techniques can be used to prevent or reduce this side effect
Oncology, Volume 56, Number 09, September 2011, Joe Munch, Bryan Tutt
Oncology, Volume 56, Number 09, September 2011, Joe Munch, Bryan Tutt
OncoLog MD Anderson's Report to Physicians (All issues)
- Novel Agents for Castrate-Resistant Prostate Cancer Include Potent Androgen Blockers and Immunotherapies: Despite progress in screening and therapy, prostate cancer continues to be a leading cause of cancer death among men worldwide
- New Targeted Therapy Offers Hope in Relapsed Hodgkin and Anaplastic large-Cell Lymphoma: The U.S. Food and Drug Administration (FDA) has approved the first new drug for Hodgkin Lymphoma since 1977
- HOUSE CALL: Colorectal Cancer Screening: Risk factors determine who should be screened and how often
- IN BRIEF: Everolimus may Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer Patients
Oncolog, Volume 56, Number 07, July 2011, Kate Newberry, Joe Munch
Oncolog, Volume 56, Number 07, July 2011, Kate Newberry, Joe Munch
OncoLog MD Anderson's Report to Physicians (All issues)
- A New Era in Treating Patients Who Have Multiple Myeloma: During the past decade, several novel treatments have extended the median survival time for patients with multiple myeloma from less than 3 years to more than 7 years, and researchers are working to further improve treatment
- Landmark Trial Shows Potential of Low-Dose Computed Tomography for Lung Cancer Screening
- HOUSE CALL: Eating Healthier May Reduce Cancer Risk: Healthy eating habits may also increase energy and heart health
- IN BRIEF: Inotuzumab Ozogamicin Shows Promise for Acute Lymphoblastic Leukemia Treatment
Oncolog, Volume 56, Number 06, June 2011, John H. Mccool, Sunni Hoseman
Oncolog, Volume 56, Number 06, June 2011, John H. Mccool, Sunni Hoseman
OncoLog MD Anderson's Report to Physicians (All issues)
- MD Anderson Celebrates 70th Anniversary: Its first clinical facility was a converted Army barracks, its first headquarters was renovated residential estate near downtown Houston, and its first cancer research was conducted by four scientists in a former horse stable
- Compass: Stage II or III Soft Tissue Sarcoma-Chemotherapy and radiation therapy before or after surgery benefit patients
Oncolog Volume 55, Number 10, October 2010, Sunni Hoseman, Stephanie Deming
Oncolog Volume 55, Number 10, October 2010, Sunni Hoseman, Stephanie Deming
OncoLog MD Anderson's Report to Physicians (All issues)
- Protecting the Patient during Radiation Theraphy: Staff expertise and equipment accuracy are essential to safe and effective treatment
- Compass Fall 2010: Stage II Colon Cancer: Adjuvant Therapy? After Surgery, some patients benefit from chemotherapy
- HOUSE CALL: Managing Cancer-Related Pain
- INBRIEF: Researchers identify Enzyme Involved in Chemotherapy Resistance